Did doubters underestimate an antipsychotic drug?
Maybe, depending on your read of positive clinical trial results from Acadia Pharma.
By way of background, the company has been running trials to try to expand the reach of its antipsychotic drug Nuplazid, which is currently approved to reduce hallucinations and psychotic symptoms in people with Parkinson’s disease. But the drug’s failure in three of four large, randomized clinical trials in recent months stoked considerable doubt as to whether it should stay on the market at all.
Yesterday, though, Acadia announced that a Phase 3 clinical trial testing Nuplazid in patients with dementia-related psychosis was stopped early because of positive efficacy. That may be a sign that Nuplazid’s critics have gotten it wrong — or, perhaps, that Acadia designed a clever trial to boost a mediocre medicine. STAT’s Adam Feuerstein ponders the possibilities.
By way of background, the company has been running trials to try to expand the reach of its antipsychotic drug Nuplazid, which is currently approved to reduce hallucinations and psychotic symptoms in people with Parkinson’s disease. But the drug’s failure in three of four large, randomized clinical trials in recent months stoked considerable doubt as to whether it should stay on the market at all.
Yesterday, though, Acadia announced that a Phase 3 clinical trial testing Nuplazid in patients with dementia-related psychosis was stopped early because of positive efficacy. That may be a sign that Nuplazid’s critics have gotten it wrong — or, perhaps, that Acadia designed a clever trial to boost a mediocre medicine. STAT’s Adam Feuerstein ponders the possibilities.
.png)
No hay comentarios:
Publicar un comentario